Assessing CAR-T Miv-Cel in Myasthenia Gravis: Srikanth Muppidi, MD

Episode 165: Addressing Cognitive Decline in Parkinson Disease

Amy Waldman overviewing phase 1 3 data

Key Takeaways on Neurorehabilitation Innovation at 2026 AAN Nirmal Surya, MD, DM

Highlights in Movement Disorders From the 2026 AMDAPP Conference

Evaluating CAR-T Miv-Cel in Stiff Person Syndrome: Amanda Piquet, MD, FAAN

Advancing Neuromuscular Research Through Collaboration and Patient-Centered Perspectives

Neurology News Network - Weekly Recap: April 25th

Core Principles and Clinical Pitfalls in Traumatic Brain Injury Management

Identifying Factors that Influence Timely Initiation of Antiamyloid Therapies in Early AD

Hormone Therapy in AD Shows Biomarker Signals but Lacks Definitive Evidence: Amanda Rodrigues, MS

How Early Environmental Detection Could Refine Parkinson's Risk Models: Rodolfo Savica, MD, PhD

Key Takeaways from the 2026 Stroke Guidelines

Neurology News Network - Weekly Recap: April 18

Addressing the True Burden of CIDP in Clinical Practice: Karen Lynch, MD, MRCPI

Episode 164: Tremor vs Dyskinesia: Practical Bedside Clues for Clinicians

Individualizing Endovascular Treatment in Acute Ischemic Stroke: Yasha Kayan, MD

The Mechanism and Promise Behind Lu AF28996 in Advanced Parkinson Disease: Johannes Streffer, MD

Neurology News Network - Weekly Recap: April 11

Comparing Long-Term Infection Risk Across Treatments for Generalized Myasthenia Gravis

Overviewing Phase 4 RESPOND Trial of Nusinersen and Zolgensma in SMA: Crystal Proud, MD

Supporting Patients in the Evolving Treatment Landscape of MS

Addressing Mental Health and Invisible Symptoms in MS Care

Context, Evidence, and Questions on the FDA's Approval of High-Dose Nusinersen: Angela Lek, PhD

The Evolving Debate Around DEVO and MEVO in Stroke Care

Neurology News Network - Weekly Recap: April 4

“Leave No Stroke Behind” Experts Discuss the Future of Stroke Care

Exploring ‘MS at a Crossroads’ Theme at the 2026 ACTRIMS Forum

Episode 163: The Clinical Reality of Seronegative Myasthenia Gravis

New Stroke Guidelines Highlight Expanding Role of Pediatric Stroke Care

Multiple System Atrophy Awareness Month and MSA Biomarkers: Wolfgang Singer, MD

Personalizing Treatment Decision Making in Multiple Sclerosis Care

From Guidelines to Practice: Challenges in Applying Updated MS Diagnostic Criteria

From Trial to Practice: How the 2024 Criteria Perform in Real-World Settings

Treating Before Symptoms: Managing RIS in the Era of Updated Multiple Sclerosis Criteria

Neurology News Network - Weekly Recap: March 28

Overviewing Key Updates in the 2024 McDonald Criteria for Multiple Sclerosis

Using the Patient Voice to Guide Clinical Research in Charcot-Marie-Tooth Disease

Giving Voice to the Patient Experience in Neuromuscular Disease

How EBV Antibodies Might Help Differentiate MS From MOGAD and NMOSD: Tanuja Chitnis, MD

Tofersen, Phase 3 Valor Study, and Clinically Significant Impacts on SOD1-ALS

Neurology News Network - Weekly Recap: March 21

2026 MDA Conference Highlights in Neuromuscular Disease Research

Exploring Long Term Safety and Real World Use of Givinostat in Duchenne Muscular Dystrophy

Bridging Imaging Biomarkers and Clinical Outcomes in MS Research: Daniel Ontaneda, MD, PhD

Analyzing Phase 2/3 ALKIVIA Study of Efgartigimod to Treat Inflammatory Myopathies

Navigating Insurance Barriers for Emerging Neuromuscular Therapies

Neurology News Network - Weekly Recap: March 14

Special Episode: AAN President Natalia Rost, MD, on Key Challenges Facing Neurology

How Migraine Trials Can Better Capture Patient-Centered Outcomes: Amaal Starling, MD, FAHS, FAAN

Neurology News Network - Weekly Recap: March 7

The Evolving Role of Neuro-Oncology in Paraneoplastic Neurologic Syndromes

Episode 162: Breaking Down INFUSE Trial Data and Real-World Eptinezumab Use

Potential of Brain-Derived Tau to Monitor Acute Brain Injury in Stroke: Steffen Tiedt, MD, PhD

Integrated Neuro-Oncology Care: Management Strategies for Paraneoplastic Neurologic Syndromes

Real-World Effectiveness of Eptinezumab After CGRP Preventive Failure: Amaal Starling, MD, FAHS

Exploring Agentic AI and its Implementation into MS Research

Chemotherapy and Targeted Therapy: Distinguishing Neurotoxicity From Paraneoplastic Syndromes

Neurology News Network - Weekly Recap: February 28

Distinguishing Paraneoplastic Neurologic Syndromes From Immune-Related Neurologic Toxicities